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| INTRODUC TI ON
Induction immunosuppressive therapy in kidney transplantation is used to reduce the incidence and severity of acute rejection, delay the initiation of calcineurin inhibitors, and/or facilitate minimization of maintenance corticosteroid or calcineurin inhibitor therapy. 1, 2 Induction immunosuppression has traditionally included T cell-depleting or non-T cell-depleting therapy. [3] [4] [5] Before the approval of rabbit anti-thymocyte globulin [rATG] in 2017, the non-T-cell-depleting monoclonal interleukin-2 (IL-2) receptor antagonists (IL2RAs) basiliximab and daclizumab (the latter was removed from the market in 2009) represented the only Food and Drug Administration (FDA)-approved induction agents for kidney transplant in the United States. 6 Rabbit ATG was first approved in the United States in 1998 for the treatment of acute rejection in renal transplantation. 7 During the past 2 decades, rATG has become the most frequently used induction agent in kidney transplantation in the United States, comprising 56% of induction therapy in kidney transplant recipients. These considerations led to this reanalysis of the current trials to support FDA approval of rATG as an induction agent in renal transplantation.
The decision to reanalyze previously completed well-controlled clinical trials for regulatory approval was based on the assessment that equipoise did not exist to allow ethical conduct of newly designed prospective randomized trials for regulatory approval for an rATG induction indication. The broad use of rATG for induction, both off-label in the United States and on-label out of the United States, has set a standard of care in kidney transplantation. Despite compelling methodologic reasons for using placebo, a placebo-controlled trial would not meet international ethical guidance permitting the use of placebo controls because withholding treatment poses considerable risks to participants and a trial would require participants to forgo treatment they would otherwise receive in clinical practice. 8 Similar ethical concerns exist for randomized studies comparing rATG with basiliximab, which may expose participants to excessive risks of harm compared with clinical practice.
Our purpose is to report the reanalysis of data from 2 clinical trials that support the use of rATG in the prophylaxis of acute rejection in kidney transplantation. This report also provides additional insights into the efficacy, dosing, and safety profile to inform treatment decisions.
| ME THODS

| Pooled analysis of patient-level data from randomized trials
Two international, randomized, controlled trials that compared rATG (Thymoglobulin ® ; Sanofi Genzyme, Cambridge, MA) with basiliximab (Simulect ® ; Novartis Pharmaceuticals, Basel, Switzerland) (NCT00235300, "rATG versus basiliximab in renal transplant" referred to as the 1010 trial) 9 and with daclizumab (Zenapax ® ; Roche, Basel, Switzerland) (NCT00682292, "daclizumab versus rATG in high-immunologic-risk renal transplant recipients" referred to as the Tacrolimus Antibody Chimeric Induction [TAXI] trial) 10 Briefly, the 2 trials included a combined total of 508 recipients of deceased donor kidney transplants, with the population in the TAXI trial being generally at immunologically higher risk for acute rejection compared with participants in the 1010 trial (>70% repeat transplants, higher PRAs). Maintenance immunosuppression in both trials included a calcineurin inhibitor (1010: cyclosporine; TAXI: tacrolimus, which was delayed in the rATG arm) as well as mycophenolate mofetil (MMF) and corticosteroids.
New statistical analysis plans for these previously reported randomized trials were developed with new prespecified analyses as agreed with the FDA with the common endpoint of treatment failure at 1 year. The FDA accepted that the composite quadruple endpoint of treatment failure including BPAR, graft loss, death, or patients lost to follow-up at 12 months posttransplant met their criteria.
The primary objective for the pooled analysis in the current study of the 1010 and TAXI trials was to assess the noninferiority of rATG versus IL2RAs for the composite endpoint, with a noninferiority margin of 10%. The determination of the noninferiority margin was based on the prospective, randomized, placebo-controlled studies included in the basiliximab and daclizumab package inserts. 11, 12 Each study was also evaluated separately by using the newly defined quadruple endpoint including a superiority test for rATG versus basiliximab in the 1010 study and a noninferiority test (with a margin of 15%) for rATG versus daclizumab in the TAXI study, using the intent-to-treat (ITT) population. An analysis based on the time-to-event was performed using the Kaplan-Meier method for those patients who were lost to follow-up in the core pooled analysis.
Secondary efficacy and safety endpoints were analyzed using data from the individual trials and from the pooled data. The individual components of the composite endpoint and treatmentemergent adverse events (TEAEs) were assessed using 2-sided 95% CI of difference between treatment groups, which was based on normal approximation of binomial distribution, and P values were obtained by comparison of treatment groups using the Fisher exact test. Kaplan-Meier analysis was used to estimate event-free survival. The difference between treatment groups for the composite endpoint (rATG -IL2RA) and 2-sided 95% CI for the difference was obtained by use of the DerSimonian-Laird method. 13 
| Data collection
Efficacy and safety analyses were performed within each of the individual and pooled studies. The number of patients with missing data was not included in the denominator unless specified.
| Pooled aggregate analysis of data from randomized trials in the literature
A systematic review of the literature was carried out to identify randomized trials of rATG induction in kidney transplant ( Figure 1 ).
An initial search of EMBASE (1999-2014) was conducted to identify published human clinical trials that mentioned "kidney transplant" and "rabbit ATG" or "rabbit antithymocyte globulin" or "rATG" or "rabbit with ATG." All related reference articles in the English literature were included and reviewed.
| Dosing
Dosing of rATG varied across the trials described here and in the published literature. In the majority of trials, rATG was initiated intraoperatively, often before graft reperfusion, and was typically given at daily doses of 1.5 mg/kg for 4 to 7 days (longer in some trials).
| Safety
The incidence, nature, and severity of TEAEs in the 1010 and TAXI trials were monitored and assessed throughout the trials for all F I G U R E 1 Systematic literature review: summary of study selection. AR, acute rejection; BPAR, biopsy-proven acute rejection; eATG, equine anti-thymocyte globulin; rATG, rabbit anti-thymocyte globulin; TAXI, "daclizumab versus anti-thymocyte globulin in high immunologicrisk renal transplant recipients." a Key words: kidney transplant; rabbit ATG, rabbit anti-thymocyte globulin; rATG, rabbit with ATG patients who received ≥1 dose of study drug. Safety data were analyzed over 12 months posttransplant. The safety data collected in the TAXI study were restricted to serious adverse events (SAEs).
| Meta-analysis
Trials in which rATG was compared with an approved comparator for induction (ie, basiliximab or daclizumab) were assessed in a meta-analysis for BPAR, graft loss, death, and, if available, a composite of these endpoints at 12 months posttransplant. 9, 10, [14] [15] [16] [17] [18] [19] [20] This meta-analysis provided information on a larger population of recipients with a broader immunologic risk of rejection than evaluated in other designated clinical trials. Aggregate data from the remaining randomized trials identified in the literature review comparing rATG with nonapproved comparators 15, 17 or maintenance regimens without induction [21] [22] [23] [24] were also evaluated for safety, efficacy, and dosing. The treatment effect was assessed by using the risk difference for each of the trials, and corresponding 2-sided 95% CIs were calculated by using normal approximation.
When a weighted average across several studies or its corresponding CI was calculated, the inverse variance was used as the weight.
For pooled analyses, a test for homogeneity was performed and the weighted averages of differences between treatment groups and 95% CI of the differences were calculated using the methods of DerSimonian and Laird. 13 
| Inclusion and exclusion criteria for the metaanalysis
| Inclusion criteria
Inclusion criteria included studies published in peer-reviewed journals and any identified unpublished manuscripts meeting the following conditions: prospective studies whereby (1) induction treatment was assigned by randomization, (2) studies had an active control treatment group that did not contain rATG, (3) patients had at least 12-month follow-up post kidney transplantation, (4) patients were recipients of a solitary kidney from a living or deceased donor, and 
| Exclusion criteria
The following studies were excluded: (1) single-center studies with <30 patients treated with rATG, (2) rejection therapy trials (nonprophylaxis), (3) clinical trials with crossover design, and (4) retrospective studies, case reports, literature reviews, or meta-analyses or when results were only available from abstracts.
| RE SULTS
| Pooled analysis of patient-level data
| Primary endpoint: quadruple composite endpoint in the trials at 12 months
Individual analysis
Each study was evaluated separately for the quadruple composite treatment-failure endpoint. Both trials achieved significance using the original statistical objective planned per protocol, with statistical superiority of rATG (24.8%) versus basiliximab (38.0%) in the 1010 trial (−13.1%, 95% CI 23.9% to −2.3%; P = .0202) and noninferiority of rATG (25.4%) versus daclizumab (33.6%) in the TAXI trial (−8.2%, 95% CI −19.9% to 3.6%) ( Table 1) .
Pooled analysis
In a pooled analysis of data from the 1010 and TAXI trials, the reported incidence of treatment failure was 25.1% and 36% in the rATG and IL2RA treatment groups, respectively. The estimated difference between the groups was −10.9% (95% CI −18.8% to −2.9%) supporting noninferiority of rATG to IL2RA (upper bound of the 95% CI below prespecified noninferiority margin), and there was a significantly lower treatment failure rate in the rATG group (upperbound of the 95% CI below 0, Table 1 ) indicating that rATG was superior to IL2RA. Components of the composite endpoint were BPAR (11.8% versus 20.9%), graft loss (11.0% versus 10.3%), death (4.3% versus 4.0%), and loss to follow-up (3.5% versus 5.5%) for rATG versus IL2RA, respectively. Results for the composite endpoint were relatively consistent across various patient subgroups analyzed as shown in Figure 2A .
Time-based analysis of the 3 components of the composite endpoint (BPAR, graft loss, or death) using study as a stratification factor indicated that treating loss to follow-up as a nonevent did not alter the conclusions of the ITT analysis. Kaplan-Meier estimates of the event-free rates for BPAR, graft loss, or death within 12 months posttransplant pooled analysis of trials 1010 and TAXI are shown in Figure 2B 
| BPAR at 12 months
When analyzed separately, 12-month BPAR rates were 12.8% versus 21.2% in the 1010 trial and 10.5% versus 20.7% in the TAXI trial for rATG and IL2RA, respectively ( Table 2) 
| Long-term follow-up data
Data from long-term follow-up of both core trials have been published. Five-year data on patients from the TAXI trial (n = 210) and 5-and 10-year data from the US patients in the 1010 trial (n = 183) have been previously described. [25] [26] [27] In comparison with basiliximab, treatment with rATG resulted in significantly lower 5-year incidences of acute rejection and acute rejection requiring antibody treatment (15% versus 27%, P = .03 and 3% versus 12%, P = .05, respectively). 25 Patients treated with rATG compared with basiliximab also had a significantly lower incidence at 5 years of the composite endpoint (acute rejection, graft loss, and death; 37% versus 51%, respectively, P = .04). 25 Treatment with rATG was also associated with a significantly lower rate of BPAR at 5 years compared with daclizumab (14.2% versus 26.0%, P = .035, respectively). 26 At 10 years posttransplant, the composite endpoint (freedom from acute rejection, graft failure, or death) was higher with rATG compared with basiliximab (32.6% versus 24.0%, respectively, P = .09). 27 The incidence of acute rejection at 10 years posttransplant was lower with rATG compared with basiliximab (21.0% versus 30.9%, respectively, P = .07). However, these studies found no meaningful differences between the rATG and basiliximab groups for graft survival or patient survival at 10 years. 27 The difference between treatment groups (rATG -IL2RA) and 2-sided 95% CI for the difference was obtained by the DerSimonian-Laird method. 1 d TAXI trial was a noninferiority study, the confidence interval approach was used to decide inferiority/noninferiority of the composite endpoint. P values were not available and therefore were not calculated for the pooled analysis. e Loss to follow-up is defined as not having BPAR (grade I-III), graft loss, or death within 12 months posttransplant, at the last evaluation severe than or comparable to IL2RA, 9,10,14,16,18-20,28 alemtuzumab, 17 or equine ATG. 15 Rabbit ATG trials have shown statistically significant reductions in the incidence of BPAR compared with IL2RA and alemtuzumab. 17 The majority of trials report BPAR rates at 12 months posttransplant of 6% to 15% with rATG. 10, 14, 19, 20, 24 BPAR is lower or comparable among trials reporting long-term follow-up. 25, 27 From these publications, prospective randomized trials were selected and were further filtered for those with at least 30 patients (single center or multicenter) and where induction therapy had been assigned by randomization, with 1 rATG treatment arm and at least 1 comparator arm (without major differences in maintenance immunosuppressive regimens between arms), and where BPAR at 12 months' follow-up was reported (Figure 1 ). Of these randomized trials, 7 compared rATG with an approved IL2RA (including the 2 core trials), 9, 10, 14, 16, [18] [19] [20] compared with alemtuzumab, 17 compared with equine ATG, 15 and 4 trials compared rATG with no antibody induction. [21] [22] [23] [24] In the randomized controlled trials in which rATG was compared with IL2RAs, the incidence of BPAR at ≥6 months posttransplant ranged from 5.9% to 18.0% in the rATG groups compared with 8.0% to 21.2% in patients randomized to IL2RA ( Figure 2D ). 9, 10, 14, 16, [18] [19] [20] In a meta-analysis of the 7 trials comparing rATG with an IL2RA, the overall difference (95% CI) in the proportion of patients with BPAR at 12 months was −4.8% (−8.6% to −0.9%) in favor of the rATG group compared with the IL2RA group ( Figure 2D ).
| Comprehensive literature review
F I G U R E 2
Forest plots for the composite endpoint within 12 months posttransplantation by demographic subgroup-trials 1010 and TAXI (ITT populations) (A). Estimates of the event free rates for biopsy proven acute rejection, graft loss, or death within 12 months posttransplantation: pooled analysis of trials 1010 and TAXI (ITT population) (B). Kaplan-Meier analysis of the sensitivity analyses for the event free rate for biopsy proven acute rejection, graft loss or death at 12 months for the 1010 and TAXI trials (ITT population) (C). Meta-analysis for biopsy-proven acute rejection at 12 months by study and overall for trials with interleukin 2-receptor antagonists as the control (D)
| Safety analysis
Safety data were collected in full in the 1010 trial. Nearly all patients reported TEAEs in the rATG (99.3%) and basiliximab (98.5%) groups.
Infections were generally more frequent in patients treated with rATG compared with those who received the control group. In the 1010 trial, urinary tract infections were the most frequent infections 
| D ISCUSS I ON
| Purpose of the analysis
The primary objective of this pooled analysis was to compare rATG versus IL2RA induction therapy for the prophylaxis of acute kidney rejection after transplant. Two randomized, controlled core trials in relatively moderate to high immunologic-risk kidney transplant recipients were deemed to be adequate, well-controlled trials to provide an evidence base for the use of rATG in induction therapy for prophylaxis of acute transplant rejection: Trial 1010 -United States and Europe 9 and TAXI -France and Belgium. 10 All patient-level data for these 2 trials were reanalyzed based on an updated prospective statistical analysis plan. After submission of these findings to the FDA, rATG received approval for the expanded US label in 2017. 
| Primary data analysis was based on the 2 randomized trials of rATG versus active comparators
| Safety profile of rATG induction therapy
The safety profile was analyzed in the 2 core randomized trials and was consistent with the known AEs seen in another trial evaluating rATG for the treatment of acute rejection. 34 Safety data was derived from 4 clinical trials supporting the extended labelling of rATG, which included a total of 730 kidney transplant recipients, of whom 405 received rATG; these 4 trials represented a diverse patient acute rejection risk profile and the use of varying maintenance immunosuppressive regimens. 9, 10, 15, 24 The safety profile in this diverse grouping of patients included known and predictable TEAEs: hematologic abnormalities, infections, and acute infusion-associated reactions.
Malignancy within 1 year posttransplant was noted in 2.5% of patients treated with rATG, but it is difficult to assign causality to these malignancies, as all patients were also taking long-term maintenance immunosuppression. The rate of malignancies was increased with rATG compared with other induction therapies, although rates were low. The incidence of malignancy and posttransplant lymphoproliferative disorder is low, which was noted in the longer follow-up (up to 10 years) reports of the 2 core clinical trials. 26, 27 TEAEs noted in the trials were generally mitigated by the use of appropriate premedications, as described in the prescribing infor- A detailed evaluation of the postmarketing experience with rATG from 1985 to 2015 was performed, and the data from this analysis were also consistent with the TEAEs seen in the clinical trials.
Contraindications of rATG are allergy or anaphylactic reaction to rabbit proteins or any expedient or active or chronic infections that preclude any additional immunosuppression. 7
| Meta-analysis
While some of the studies included in the meta-analysis had results published for follow-up periods longer than 12 months, only the publication reporting the 12-month results were included in the analysis. The formal meta-analysis, which evaluated 1293 kidney transplant recipients of which 662 received rATG, demonstrated that, in well-controlled peerreviewed clinical trials comparing rATG with active controls, the overall incidence of BPAR at 12 months tended to be favorable for rATG in all 9 trials, and BPAR at 12 months was statistically lower with rATG compared with just the IL2RA in 7 trials ( Figure 2D ). 9, 10, 14, 16, [18] [19] [20] 
| Study limitations
Limitations included the absence of recent phase 3 trials and the historic age of the trials in the analyses. Differences in the maintenance treatment within and between trials meant that these were not matched in many trials. One limitation of the TAXI trial was that only SAEs were documented in the study. 10 Also, our reanalysis may not have been fully representative of the transplant recipient population, because the TAXI trial only used kidneys from deceased donors and therefore the recipients were at higher risk of delayed graft function. Other limitations include equal weighting was given to the quadruple endpoint, there was variation in rATG dosing within and between trials, and maintenance immunosuppression was not standardized between trials (cyclosporine versus tacrolimus). Abramowicz has no conflicts of interest to disclose.
| CON CLUS IONS
DATA AVA I L A B I L I T Y S TAT E M E N T
Qualified researchers may request access to patient-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com.
